[
  {
    "ts": null,
    "headline": "Merck Swoops In On Buyout Bonanza With A $9.2 Billion Cidara Therapeutics Deal",
    "summary": "Cidara Therapeutics shares doubled, and then some, on Friday after Merck agreed to buy the biotech company for $9.2 billion.",
    "url": "https://finnhub.io/api/news?id=0cd1f99d0e3471fa453751dc46fb7b94c33ae1b96c83f28600c789eb2d478a84",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763140630,
      "headline": "Merck Swoops In On Buyout Bonanza With A $9.2 Billion Cidara Therapeutics Deal",
      "id": 137480298,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Cidara Therapeutics shares doubled, and then some, on Friday after Merck agreed to buy the biotech company for $9.2 billion.",
      "url": "https://finnhub.io/api/news?id=0cd1f99d0e3471fa453751dc46fb7b94c33ae1b96c83f28600c789eb2d478a84"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Today: Dow Jones Climbs Off Lows As Nvidia Jumps; Micron, Palantir Lead Nasdaq (Live Coverage)",
    "summary": "Stock Market Today: The Dow Jones index dropped 400 points Friday. But Nvidia and Palantir recovered well off session lows.",
    "url": "https://finnhub.io/api/news?id=333e9e8f32ba76abe1fe6dfb734d7c4bfe4aa366598178d2283386f8789605e9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763140522,
      "headline": "Stock Market Today: Dow Jones Climbs Off Lows As Nvidia Jumps; Micron, Palantir Lead Nasdaq (Live Coverage)",
      "id": 137479962,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Stock Market Today: The Dow Jones index dropped 400 points Friday. But Nvidia and Palantir recovered well off session lows.",
      "url": "https://finnhub.io/api/news?id=333e9e8f32ba76abe1fe6dfb734d7c4bfe4aa366598178d2283386f8789605e9"
    }
  },
  {
    "ts": null,
    "headline": "Merck to buy Cidara for $9.2B, Netflix nears 10-for-1 stock split",
    "summary": "Yahoo Finance host Julie Hyman tracks today's top moving stocks and biggest market stories in this Market Minute, including tech names Nvidia (NVDA), Tesla (TSLA), and Broadcom (AVGO) in recovery mode from Thursday's tech sell-off, Merck's (MRK) plans to buy Cidara Therapeutics (CDTX) in a deal worth up to $9.2 billion, and Netflix (NFLX) prepares to execute its 10-for-1 stock split. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
    "url": "https://finnhub.io/api/news?id=f91ed75ed0feaf5a146d457272d090f6c5e0456908b9de9de81fe474d94fc87a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763140002,
      "headline": "Merck to buy Cidara for $9.2B, Netflix nears 10-for-1 stock split",
      "id": 137479964,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Yahoo Finance host Julie Hyman tracks today's top moving stocks and biggest market stories in this Market Minute, including tech names Nvidia (NVDA), Tesla (TSLA), and Broadcom (AVGO) in recovery mode from Thursday's tech sell-off, Merck's (MRK) plans to buy Cidara Therapeutics (CDTX) in a deal worth up to $9.2 billion, and Netflix (NFLX) prepares to execute its 10-for-1 stock split. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
      "url": "https://finnhub.io/api/news?id=f91ed75ed0feaf5a146d457272d090f6c5e0456908b9de9de81fe474d94fc87a"
    }
  },
  {
    "ts": null,
    "headline": "Top Midday Stories: Merck to Acquire Cidara Therapeutics for $9.2 Billion; Walmart Names John Furner as CEO",
    "summary": "The S&P 500 and Nasdaq Composite rose in midday trading, erasing earlier declines, and the Dow Jones",
    "url": "https://finnhub.io/api/news?id=60ec423a43f98e97456d204577509c7ce8cc49ab239a5d70b7658ac6f1aadc90",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763139035,
      "headline": "Top Midday Stories: Merck to Acquire Cidara Therapeutics for $9.2 Billion; Walmart Names John Furner as CEO",
      "id": 137480153,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The S&P 500 and Nasdaq Composite rose in midday trading, erasing earlier declines, and the Dow Jones",
      "url": "https://finnhub.io/api/news?id=60ec423a43f98e97456d204577509c7ce8cc49ab239a5d70b7658ac6f1aadc90"
    }
  },
  {
    "ts": null,
    "headline": "Merck Is Paying Up for Flu Biotech as M&A Spree Continues",
    "summary": "Merck has agreed to pay a hefty premium for a biotech making a new flu prevention drug, as it braces for the expiration of the patents protecting its top-selling cancer treatment Keytruda.  It is the latest signal that competition is intense as the biggest pharmaceutical companies scramble to pad their drug pipelines.  Merck said Friday it will pay $9.2 billion for  Cidara Therapeutics  or $221.50 per share in cash, more than double the share price before the news.",
    "url": "https://finnhub.io/api/news?id=090adcc8018fca6112c353fe131c17ece7193f03eb65032190b72985ab64a6cc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763137800,
      "headline": "Merck Is Paying Up for Flu Biotech as M&A Spree Continues",
      "id": 137480302,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck has agreed to pay a hefty premium for a biotech making a new flu prevention drug, as it braces for the expiration of the patents protecting its top-selling cancer treatment Keytruda.  It is the latest signal that competition is intense as the biggest pharmaceutical companies scramble to pad their drug pipelines.  Merck said Friday it will pay $9.2 billion for  Cidara Therapeutics  or $221.50 per share in cash, more than double the share price before the news.",
      "url": "https://finnhub.io/api/news?id=090adcc8018fca6112c353fe131c17ece7193f03eb65032190b72985ab64a6cc"
    }
  },
  {
    "ts": null,
    "headline": "WBD amends CEO Zaslav's contract, StubHub withholds Q4 guidance",
    "summary": "Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including Merck (MRK) pursuing an acquisition of Cidara Therapeutics (CDTX) in a deal valued at $9.2 billion, the Wall Street Journal reporting that several media players are preparing bids on Warner Bros. Discovery (WBD), and StubHub (STUB) shares plunging after withholding its fourth quarter guidance. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
    "url": "https://finnhub.io/api/news?id=31b6c17a6624b82af8e5028e003f0c847aeec321b103c1cb736354eee90cd4aa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763135221,
      "headline": "WBD amends CEO Zaslav's contract, StubHub withholds Q4 guidance",
      "id": 137480140,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Market Catalysts host Julie Hyman tracks several of the day's top trending stock tickers, including Merck (MRK) pursuing an acquisition of Cidara Therapeutics (CDTX) in a deal valued at $9.2 billion, the Wall Street Journal reporting that several media players are preparing bids on Warner Bros. Discovery (WBD), and StubHub (STUB) shares plunging after withholding its fourth quarter guidance. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.",
      "url": "https://finnhub.io/api/news?id=31b6c17a6624b82af8e5028e003f0c847aeec321b103c1cb736354eee90cd4aa"
    }
  },
  {
    "ts": null,
    "headline": "Here's Why Merck (MRK) is a Strong Growth Stock",
    "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
    "url": "https://finnhub.io/api/news?id=99f3bc5dcb82366938aec73af1a7352a556d0bce4911ac6a52359c761e1cad19",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763131504,
      "headline": "Here's Why Merck (MRK) is a Strong Growth Stock",
      "id": 137480304,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.",
      "url": "https://finnhub.io/api/news?id=99f3bc5dcb82366938aec73af1a7352a556d0bce4911ac6a52359c761e1cad19"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Decline Premarket Friday",
    "summary": "Health care stocks were declining premarket Friday, with the Health Care Select Sector SPDR Fund (XL",
    "url": "https://finnhub.io/api/news?id=1b11f933c9b7d8453aa001032d1eaa57de642da24b7099d2c5a1ee77ce3944d4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763129990,
      "headline": "Sector Update: Health Care Stocks Decline Premarket Friday",
      "id": 137480147,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Health care stocks were declining premarket Friday, with the Health Care Select Sector SPDR Fund (XL",
      "url": "https://finnhub.io/api/news?id=1b11f933c9b7d8453aa001032d1eaa57de642da24b7099d2c5a1ee77ce3944d4"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Weighs Tech Valuations, Fed Outlook as US Equity Futures Fall Pre-Bell",
    "summary": "US equity futures were down ahead of Friday's opening bell, extending losses from the previous sessi",
    "url": "https://finnhub.io/api/news?id=03b4851398e34c343c881e923791200534991bea02a40de20e207d43c01dab6c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763129529,
      "headline": "Wall Street Weighs Tech Valuations, Fed Outlook as US Equity Futures Fall Pre-Bell",
      "id": 137480108,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "US equity futures were down ahead of Friday's opening bell, extending losses from the previous sessi",
      "url": "https://finnhub.io/api/news?id=03b4851398e34c343c881e923791200534991bea02a40de20e207d43c01dab6c"
    }
  },
  {
    "ts": null,
    "headline": "Merck to Acquire Cidara Therapeutics in $9.2 Billion Deal",
    "summary": "Merck (MRK) on Friday agreed to acquire immunotherapy developer Cidara Therapeutics (CDTX) in a deal",
    "url": "https://finnhub.io/api/news?id=cddf6b9ee651bf2f7f1ed8f644309fb52a68b175000714aa6750876af99512f9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763129155,
      "headline": "Merck to Acquire Cidara Therapeutics in $9.2 Billion Deal",
      "id": 137480307,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (MRK) on Friday agreed to acquire immunotherapy developer Cidara Therapeutics (CDTX) in a deal",
      "url": "https://finnhub.io/api/news?id=cddf6b9ee651bf2f7f1ed8f644309fb52a68b175000714aa6750876af99512f9"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Roundup: Cisco Surges, Oracle Sinks Amid Growing AI Fears",
    "summary": "Market mood is mercurial and jittery. Cisco vs. Oracle: a split in AI infrastructure plays.",
    "url": "https://finnhub.io/api/news?id=8e15994140831b7df83a365386b0e3951e0e442cd0352a0b705eb5b8a92f36fa",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763127900,
      "headline": "Wall Street Roundup: Cisco Surges, Oracle Sinks Amid Growing AI Fears",
      "id": 137481256,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1193524207/image_1193524207.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Market mood is mercurial and jittery. Cisco vs. Oracle: a split in AI infrastructure plays.",
      "url": "https://finnhub.io/api/news?id=8e15994140831b7df83a365386b0e3951e0e442cd0352a0b705eb5b8a92f36fa"
    }
  },
  {
    "ts": null,
    "headline": "Cidara's Narrow Spread: The Bidding War Is Over",
    "summary": "Cidara Therapeutics, Inc. stock jumps on Merck & Co., Inc.âs $221.50 takeover bid. Discover deal insights, upside, and risks for investors. Click for more on CDTX.",
    "url": "https://finnhub.io/api/news?id=08a45b1b87c01e1867b22ed5f8b9e06ab0e78e19856a46202d7048a9d0ad1df7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763126751,
      "headline": "Cidara's Narrow Spread: The Bidding War Is Over",
      "id": 137481169,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2172812906/image_2172812906.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Cidara Therapeutics, Inc. stock jumps on Merck & Co., Inc.âs $221.50 takeover bid. Discover deal insights, upside, and risks for investors. Click for more on CDTX.",
      "url": "https://finnhub.io/api/news?id=08a45b1b87c01e1867b22ed5f8b9e06ab0e78e19856a46202d7048a9d0ad1df7"
    }
  },
  {
    "ts": null,
    "headline": "Do You Believe in Merck & Co.’s (MRK) Upside Potential?",
    "summary": "Antipodes Partners recently published its “Antipodes Global Value Strategy” third-quarter 2025 investor letter, highlighting the key performance stocks, portfolio changes, and the market outlook. A copy of the letter can be downloaded here. In the quarter, global equities rose positively, supported by easing trade tensions, excitement around AI, and expectations of rate cuts by the […]",
    "url": "https://finnhub.io/api/news?id=d137e1befff3e509e3f612fa67c60fa4ad1c3ee8efcd34ff17ad35a222f9abbe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763126647,
      "headline": "Do You Believe in Merck & Co.’s (MRK) Upside Potential?",
      "id": 137480308,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Antipodes Partners recently published its “Antipodes Global Value Strategy” third-quarter 2025 investor letter, highlighting the key performance stocks, portfolio changes, and the market outlook. A copy of the letter can be downloaded here. In the quarter, global equities rose positively, supported by easing trade tensions, excitement around AI, and expectations of rate cuts by the […]",
      "url": "https://finnhub.io/api/news?id=d137e1befff3e509e3f612fa67c60fa4ad1c3ee8efcd34ff17ad35a222f9abbe"
    }
  },
  {
    "ts": null,
    "headline": "Pharma ETFs in Spotlight Following Robust Q3 Earnings Results",
    "summary": "Pharma ETFs like IHE and PPH are rallying as strong Q3 earnings across major pharmaceutical companies lift sector sentiment.",
    "url": "https://finnhub.io/api/news?id=469476e1c5e3b37cd8290dd50c679e28e3d6eb5ae8047acb8f21f3f31eca06ee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763125140,
      "headline": "Pharma ETFs in Spotlight Following Robust Q3 Earnings Results",
      "id": 137480131,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Pharma ETFs like IHE and PPH are rallying as strong Q3 earnings across major pharmaceutical companies lift sector sentiment.",
      "url": "https://finnhub.io/api/news?id=469476e1c5e3b37cd8290dd50c679e28e3d6eb5ae8047acb8f21f3f31eca06ee"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co agrees to buy Cidara Therapeutics in USD9.2 billion deal",
    "summary": "Merck & Co agrees to buy Cidara Therapeutics in USD9.2 billion deal",
    "url": "https://finnhub.io/api/news?id=17a66a236a407db3fd675972dae766b8ea201d64379f50ed88fae96e26254c8a",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763123934,
      "headline": "Merck & Co agrees to buy Cidara Therapeutics in USD9.2 billion deal",
      "id": 137478628,
      "image": "",
      "related": "MRK",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=17a66a236a407db3fd675972dae766b8ea201d64379f50ed88fae96e26254c8a"
    }
  },
  {
    "ts": null,
    "headline": "Merck to Buy Cidara Therapeutics in $9.2 Billion Deal",
    "summary": "Merck Co. has struck a $9.2 billion deal to buy biotechnology company Cidara Therapeutics in a move that bolsters the drugmaker’s respiratory portfolio.",
    "url": "https://finnhub.io/api/news?id=d9c3d690d07ae79233f8390793b9668806c744a1afbab86ff518d15456e82b10",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763122740,
      "headline": "Merck to Buy Cidara Therapeutics in $9.2 Billion Deal",
      "id": 137480310,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck Co. has struck a $9.2 billion deal to buy biotechnology company Cidara Therapeutics in a move that bolsters the drugmaker’s respiratory portfolio.",
      "url": "https://finnhub.io/api/news?id=d9c3d690d07ae79233f8390793b9668806c744a1afbab86ff518d15456e82b10"
    }
  },
  {
    "ts": null,
    "headline": "Merck Agrees to Acquire Cidara Therapeutics for $9.2 Billion",
    "summary": "Merck (MRK) said Friday it has agreed for a subsidiary to acquire all outstanding shares of Cidara T",
    "url": "https://finnhub.io/api/news?id=47766e542f7a592ea4caa783d270c8364261cda1d7f492bf2ba4d1c8bd423d0c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763121887,
      "headline": "Merck Agrees to Acquire Cidara Therapeutics for $9.2 Billion",
      "id": 137480311,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (MRK) said Friday it has agreed for a subsidiary to acquire all outstanding shares of Cidara T",
      "url": "https://finnhub.io/api/news?id=47766e542f7a592ea4caa783d270c8364261cda1d7f492bf2ba4d1c8bd423d0c"
    }
  },
  {
    "ts": null,
    "headline": "Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent",
    "summary": "RAHWAY, N.J. & SAN DIEGO, Calif., November 14, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Cidara Therapeutics, Inc. (Nasdaq: CDTX) (\"Cidara\"), a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Cidara for $221.50 per share in cash, for a total transaction value of approximately $9.2 billion.",
    "url": "https://finnhub.io/api/news?id=b61e37b9ba10cebeed40b24937e7c3c678782d22a31f19b6c3f5bb4231d1286f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763120700,
      "headline": "Merck to Acquire Cidara Therapeutics, Inc., Diversifying Its Portfolio to Include Late-Phase Antiviral Agent",
      "id": 137480312,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J. & SAN DIEGO, Calif., November 14, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Cidara Therapeutics, Inc. (Nasdaq: CDTX) (\"Cidara\"), a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Cidara for $221.50 per share in cash, for a total transaction value of approximately $9.2 billion.",
      "url": "https://finnhub.io/api/news?id=b61e37b9ba10cebeed40b24937e7c3c678782d22a31f19b6c3f5bb4231d1286f"
    }
  },
  {
    "ts": null,
    "headline": "Merck's Cidara Buyout Is An Opportunistic Win For Both Parties - Here's Why",
    "summary": "Merck & Co., Inc. acquires Cidara Therapeutics, Inc. for $9.2bn, boosting its pipeline with CD388's strong flu data. Click for my look at the MRK and CDTX deal.",
    "url": "https://finnhub.io/api/news?id=394d9262b103694619c954892caa6a9eb2c5131d8ac7fda0896095ed07092cdb",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763117788,
      "headline": "Merck's Cidara Buyout Is An Opportunistic Win For Both Parties - Here's Why",
      "id": 137479337,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2222078293/image_2222078293.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Merck & Co., Inc. acquires Cidara Therapeutics, Inc. for $9.2bn, boosting its pipeline with CD388's strong flu data. Click for my look at the MRK and CDTX deal.",
      "url": "https://finnhub.io/api/news?id=394d9262b103694619c954892caa6a9eb2c5131d8ac7fda0896095ed07092cdb"
    }
  },
  {
    "ts": null,
    "headline": "Recombinant Human Fibroblast Growth Factor Global Market Forecast 2025-2030: Markets Benefit from Strategic Investments and Collaborations",
    "summary": "Recombinant human fibroblast growth factors offer growth prospects in regenerative medicine and cosmetics, driven by efficient production systems. Key opportunities arise from applications in wound healing, tissue engineering, and cosmetics. Notable firms include Thermo Fisher and Merck.Dublin, Nov. 14, 2025 (GLOBE NEWSWIRE) -- The \"Recombinant Human Fibroblast Growth Factor Market - Global Forecast 2025-2030\" report has been added to ResearchAndMarkets.com's offering. Recombinant human fibrobla",
    "url": "https://finnhub.io/api/news?id=464e451357a0d773a8224cab56c0563a4083c50f620d9752145f0ebee61abcd9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763112600,
      "headline": "Recombinant Human Fibroblast Growth Factor Global Market Forecast 2025-2030: Markets Benefit from Strategic Investments and Collaborations",
      "id": 137478298,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Recombinant human fibroblast growth factors offer growth prospects in regenerative medicine and cosmetics, driven by efficient production systems. Key opportunities arise from applications in wound healing, tissue engineering, and cosmetics. Notable firms include Thermo Fisher and Merck.Dublin, Nov. 14, 2025 (GLOBE NEWSWIRE) -- The \"Recombinant Human Fibroblast Growth Factor Market - Global Forecast 2025-2030\" report has been added to ResearchAndMarkets.com's offering. Recombinant human fibrobla",
      "url": "https://finnhub.io/api/news?id=464e451357a0d773a8224cab56c0563a4083c50f620d9752145f0ebee61abcd9"
    }
  },
  {
    "ts": null,
    "headline": "Stocks making the biggest premarket moves: Warner Bros. Discovery, Cidara Therapeutics, Avadel Pharmaceuticals and more",
    "summary": "These are some of the stocks posting the largest moves in premarket trading.",
    "url": "https://finnhub.io/api/news?id=f72592a4bd01945f62fb0535e290a0d988da6ce4dc0e092329491d4254272441",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763109307,
      "headline": "Stocks making the biggest premarket moves: Warner Bros. Discovery, Cidara Therapeutics, Avadel Pharmaceuticals and more",
      "id": 137479779,
      "image": "https://image.cnbcfm.com/api/v1/image/108215227-1761133898442-gettyimages-2242437594-_m0a9907_fwkwmzx1.jpeg?v=1761133927&w=1920&h=1080",
      "related": "MRK",
      "source": "CNBC",
      "summary": "These are some of the stocks posting the largest moves in premarket trading. ",
      "url": "https://finnhub.io/api/news?id=f72592a4bd01945f62fb0535e290a0d988da6ce4dc0e092329491d4254272441"
    }
  },
  {
    "ts": null,
    "headline": "Merck stakes $9.2B on Cidara and its long-acting flu drug",
    "summary": "The deal, one of two multibillion-dollar buyouts from Merck this year, centers around a drug that could become an alternative to vaccines for flu prevention.",
    "url": "https://finnhub.io/api/news?id=7b37e50212e54dc2d5cfff002cc6c9a0a14b2b6d516c5076f58079b1259d03e6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763107980,
      "headline": "Merck stakes $9.2B on Cidara and its long-acting flu drug",
      "id": 137480313,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The deal, one of two multibillion-dollar buyouts from Merck this year, centers around a drug that could become an alternative to vaccines for flu prevention.",
      "url": "https://finnhub.io/api/news?id=7b37e50212e54dc2d5cfff002cc6c9a0a14b2b6d516c5076f58079b1259d03e6"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Breakfast Podcast: Merck Talks Send Cidara Soaring",
    "summary": "Merck seen nearing acquisition of Cidara Therapeutics in deal potentially above $3.3 billion. U.S., Argentina to open markets to key products in trade framework. DoorDash reveals breach.",
    "url": "https://finnhub.io/api/news?id=1dcc378f1783f66c4b7ef68ab123b97e1a22a0e1f0578549e52d68a410e17786",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763100599,
      "headline": "Wall Street Breakfast Podcast: Merck Talks Send Cidara Soaring",
      "id": 137478111,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2201814990/image_2201814990.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Merck seen nearing acquisition of Cidara Therapeutics in deal potentially above $3.3 billion. U.S., Argentina to open markets to key products in trade framework. DoorDash reveals breach.",
      "url": "https://finnhub.io/api/news?id=1dcc378f1783f66c4b7ef68ab123b97e1a22a0e1f0578549e52d68a410e17786"
    }
  },
  {
    "ts": null,
    "headline": "Merck (MRK) Delivers Strong Q3 2025 Earnings as Oncology Sales Drive Revenue Growth",
    "summary": "Merck & Co. Inc. (NYSE:MRK) ranks among the best long-term stocks to buy according to D. E. Shaw. On October 30, Merck & Co. Inc. (NYSE:MRK) announced its Q3 2025 earnings, showing better-than-expected financial results despite uneven product portfolio performance. The company’s revenue of $17.3 billion crossed analyst estimates of $16.98 billion, while its EPS […]",
    "url": "https://finnhub.io/api/news?id=e2498bc6565bb749738632b4eee74ecd47cf1659234823643509068ae793a548",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763094022,
      "headline": "Merck (MRK) Delivers Strong Q3 2025 Earnings as Oncology Sales Drive Revenue Growth",
      "id": 137476946,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck & Co. Inc. (NYSE:MRK) ranks among the best long-term stocks to buy according to D. E. Shaw. On October 30, Merck & Co. Inc. (NYSE:MRK) announced its Q3 2025 earnings, showing better-than-expected financial results despite uneven product portfolio performance. The company’s revenue of $17.3 billion crossed analyst estimates of $16.98 billion, while its EPS […]",
      "url": "https://finnhub.io/api/news?id=e2498bc6565bb749738632b4eee74ecd47cf1659234823643509068ae793a548"
    }
  },
  {
    "ts": null,
    "headline": "Merck nears deal for flu-prevention biotech Cidara",
    "summary": "Merck is nearing a deal to buy Cidara Therapeutics, a drugmaker pioneering a long-acting antibody medicine that protects against flu, after besting...",
    "url": "https://finnhub.io/api/news?id=3566f9475e27427ffb6e37e9cff82f995ef396a72960459d0c98bc19fa66a659",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763078863,
      "headline": "Merck nears deal for flu-prevention biotech Cidara",
      "id": 137476947,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck is nearing a deal to buy Cidara Therapeutics, a drugmaker pioneering a long-acting antibody medicine that protects against flu, after besting...",
      "url": "https://finnhub.io/api/news?id=3566f9475e27427ffb6e37e9cff82f995ef396a72960459d0c98bc19fa66a659"
    }
  }
]